Altimmune Inc
ALT
NASDAQ
Biotechnology
$2.94
USD
+0.06 (+2.08%)
At close: Aug 14, 2026, 4:00 PM EDT
Market Cap $559.11M
Volume 3.0M
Revenue
$31,000
TTM
+55.0%
YoY
Gross Margin
100%
TTM
0.0%
YoY
Net Income
$-91.76M
TTM
-4.6%
YoY
Operating Cash Flow
$-76.51M
TTM
+6.2%
YoY
Revenue & Net Income
USD Millions
Margins Trend
Percent of revenue
Income Statement Detail
USD Millions, except per-share and share count figures
Metric | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 | Q2 2026 |
|---|---|---|---|---|---|
Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
YoY Growth | 0.0% | 0.0% | +420.0% | -100.0% | -100.0% |
Cost of Revenue | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Gross Profit | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Selling, General & Administrative | 5.7 | 5.9 | 10.5 | 8.1 | 7.6 |
Other Operating Expenses | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Total Operating Expenses | 22.9 | 20.9 | 28.9 | 24.2 | 26.2 |
Operating Income | -22.9 | -20.9 | -28.9 | -24.2 | -26.2 |
EBITDA | -22.9 | -20.8 | -28.9 | -24.2 | -26.2 |
Other Income / Expense | -0.1 | -0.1 | -0.0 | -0.2 | -0.0 |
Total Other Income / Expense | 0.8 | 1.8 | 1.5 | 1.7 | 3.4 |
Income Before Income Taxes | -22.1 | -19.0 | -27.4 | -22.6 | -22.8 |
Income Taxes | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
Net Income | -22.1 | -19.0 | -27.4 | -22.6 | -22.8 |
Consolidated Net Income / Loss | -22.1 | -19.0 | -27.4 | -22.6 | -22.8 |
Net Income Attributable to Common Shareholders | -22.1 | -19.0 | -27.4 | -22.9 | -22.8 |
Basic EPS | -$0.27 | -$0.21 | -$0.26 | -$0.18 | -$0.12 |
Diluted EPS | -$0.27 | -$0.21 | -$0.26 | -$0.18 | -$0.12 |
Basic Shares Outstanding | 81.5M | 89.4M | 106.0M | 124.5M | 185.4M |
Diluted Shares Outstanding | 81.5M | 89.4M | 106.0M | 124.5M | 185.4M |